Attention

The opinions expressed by columnists are their own and do not represent our advertisers

Wednesday, August 17, 2011

FDA Approves Gene-Targeting Skin Cancer Drug

WASHINGTON (AP) - The Food and Drug Administration has approved a first-of-a-kind drug to treat the deadliest form of skin cancer by targeting a particular genetic mutation found in about half of patients.

The pill-based drug called Zelboraf, made by Roche, is the first treatment for melanoma that targets a specific gene found in skin-cancer tumors. The FDA said Wednesday it also approved a test to screen patients for the mutation.

Melanoma is the fastest-growing form of cancer in terms of new diagnoses. Researchers attribute the acceleration to longer life expectancies among the elderly and increased indoor tanning by the young.

More

1 comment:

Anonymous said...

"OMG, even more reason why we shouldn't be funding NIH, NSF, and other science organizations. They don't do a thing for us."